Molecular Vision: Chowers, Mol Vis 2008; 14:2263-2271. Table 3

Table 3. Frequency of HTRA1 (rs11200638) alleles and genotypes in NVAMD patients and unaffected controls

*HTRA1* (rs1200638)	AMD	Unaffected	p	OR (95% CI)
By allele
Entire population (G/A; %)	325/185 (63.7/36.3)	197/41 (82.8/17.2)	<0.0001	2.7 (1.9–4)
Ashkenazi Jews	212/114 (65/35)	114/22 (83.8/16.2)	<0.0001	2.8 (1.7–4.6)
Sephardic Jews	95/55 (63/37)	65/15 (81.3/18.7)	0.0065	2.5 (1.3–4.8)
Arabs	10/12 (45.4/54.6)	17/3 (0.85/0.15)	0.01	6.8 (1.5–30.1)
By genotype
Entire population			<0.0001
GG (%)	116 (45.5)	81 (68.1)
GA (%)	93 (36.5)	35 (29.4)	0.013	1.8 (1.1–3.0)
AA (%)	46 (18.0)	3 (2.5)	<0.0001	10.7 (3.2–35.7)
Ashkenazi Jews			0.011
GG (%)	80 (49.1)	48 (70.6)
GA (%)	52 (31.9)	18 (26.5)	0.24	1.5 (3–0.76)
AA (%)	31 (19)	2 (2.9)	0.009	7.2 (31.2–1.6)
Sephardic Jews			0.02
GG (%)	30 (40)	26 (65)
GA (%)	35 (46.7)	13 (32.5)	0.044	2.3 (5.3–1.02)
AA (%)	10 (13.3)	1 (2.5)	0.046	8.7 (71.5–1.04)
Arabs#			0.05
GG (%)	4 (36.4)	7 (70)
GA (%)	2 (18.1)	3 (30)
AA (%)	5 (45.5)	0 (0)

Comparison of the frequency (%) of the HTRA1 (rs11200638) variant between NVAMD patients and controls in the entire Israeli population and in the Ashkenazi, Sephardic, and Arab subpopulations. Increased prevalence of the A variant was associated with the disease in the entire population as well as in Ashkenazi, Sephardic, and Arab subpopulation. CI- confidence interval, OR- odds ratio. The hash mark represents there were too few Arabs to obtain reliable ORs and CIs for analysis of genotypes in this sub population.